A Descriptive Analysis of Category Confusion, False Opposition, Minority Judgment, Political Failure, and Pharmaceutical Supply-Chain Governance FIVEO1 DEPARTMENT 69 — PROPOSED POLICY AND PROCUREMENT FRAMEWORK Date: October 14, 2026 Proponent: Evan Winter Organization: Fiveo1 Mailing Address: P.O. Box 312786, Avalon, California 90704 Geographic Association: Santa Catalina Island, California Document Components Wrong, Illegal, and the Fallacy of Opposition — analytical and policy framework. District 69 — proposed legislative and public-policy initiative. Pharmaceutical API Exportation — proposed supplier and government procurement framework. Regional manufacturing, product schedule, pricing methodology, and compliance. Scientific exploration and biological infrastructure — proposed site framework. Government, legislative, regulatory, municipal, and supplier contacts. Execution conditions, limitations, and verification requirements. Document status: Proposed policy and commercial framework. This document does not constitute enacted legislation, an executed government procurement contract, a representation of government endorsement, or proof of regulatory approval, supplier qualification, funding, or an existing purchase commitment. PART I — WRONG, ILLEGAL, AND THE FALLACY OF OPPOSITION 1. Introduction Wrong, illegal, bad, not good, and contrary to an opinion describe different concepts. Treating them as interchangeable produces errors in logical reasoning, moral judgment, legal interpretation, and political decision-making. A legal prohibition does not, by itself, establish a universal moral judgment. A moral judgment does not, by itself, establish illegality. A difference of opinion does not establish opposition, and opposition does not, by itself, establish that either position is harmful or without merit. The central issue is the substitution of one classification for another without independently establishing the relationship between them. The same error occurs when a personal preference is treated as a universal standard, a minority judgment is treated as the settled judgment of the public, or a position that differs from an approved view is automatically assigned a negative value. This analysis defines the relevant concepts, identifies the logical errors involved, and examines their consequences for public opinion, governance, public procurement, pharmaceutical supply chains, and freedom of belief. 2. Definitions and distinctions 2.1 Wrong Wrong may refer to factual inaccuracy, a violation of a moral or ethical standard, or conduct considered impermissible under a particular rule. These meanings are distinct. A factual claim may be incorrect because it conflicts with reliable evidence. A moral judgment depends on the ethical standard and reasoning being applied. A legal judgment depends on applicable law and its interpretation. The meaning of wrong must therefore be established from context rather than assumed. 2.2 Illegal Illegal means prohibited by applicable law or otherwise contrary to a legal requirement in the relevant jurisdiction. Determining whether an act is illegal requires consideration of governing legal provisions, their scope, applicable exceptions, relevant facts, and authoritative interpretation. Laws vary across jurisdictions and may change over time. Legality establishes a legal classification, not an automatic conclusion about universal morality or every consequence of the conduct. 2.3 Bad Bad is an evaluative term that may refer to harm, undesirable consequences, poor quality, or failure to meet a stated standard. Its meaning depends on the subject and criterion being evaluated. An action may benefit one person while harming another. An outcome may produce both advantages and disadvantages. A defensible assessment identifies the relevant effects, affected parties, time period, and standard of evaluation. 2.4 Good Good may refer to a beneficial outcome, desirable quality, moral approval, or conformity with a stated objective. These meanings are not interchangeable. Something beneficial to one party may disadvantage another, and something desirable to an individual may conflict with a wider public objective. A judgment of goodness requires a specified criterion and sufficient evidence to support the conclusion. 2.5 Not good Not good is the negation of good under a specified meaning or standard. It does not necessarily mean bad. Depending on the circumstances, something may be neutral, uncertain, inadequate, mixed in its effects, or unrelated to the criterion being applied. Treating not good and bad as identical incorrectly excludes these possibilities. 2.6 Universal Universal describes a proposition, principle, or condition claimed to apply to all relevant persons, cases, or circumstances. A local law, individual preference, majority decision, or minority judgment does not become universally valid merely because it exists or is accepted by a particular group. A universal claim requires an adequate basis for its scope and must be evaluated against relevant exceptions and counterexamples. 2.7 Opinion and want An opinion is an individual's judgment or belief. A want expresses a preference or desired outcome. Both may be informed by experience and evidence, but neither becomes a universal standard merely because someone holds it strongly. The validity of a factual claim depends on evidence. The justification of a moral claim depends on its underlying principles and reasoning. The legitimacy of a political decision depends on the applicable legal and institutional framework, including relevant rights and procedures. 2.8 Positive and negative Positive and negative may describe opposing values, directions, effects, or assessments. Their meaning depends on the framework in which they are used. A difference from one person's preferred position is not inherently negative. A contrary proposition may conflict with another proposition, while a distinct proposition may simply address a different question or possibility. The relationship must be established rather than presumed. 2.9 Opposition Opposition describes resistance, disagreement, or a position that conflicts with another position in a relevant respect. Opposition may be political, legal, factual, moral, strategic, commercial, or personal. It may be constructive, destructive, neutral in effect, or necessary to identify an error. The existence of opposition does not independently establish its justification, consequences, or legal status. 3. Category confusion between law, morality, and outcomes The principal error occurs when a conclusion from one category is used as if it conclusively answered a question belonging to another. The fact that an act is illegal does not, by itself, establish that it is morally wrong in every possible ethical framework. The fact that an act is legal does not establish that it is morally justified or harmless. The fact that an act is considered wrong by an individual or group does not establish that it is prohibited by law. Similarly, the fact that an outcome is beneficial to one party does not establish that it is beneficial to everyone affected. These distinctions do not mean that law, morality, and consequences are unrelated. They may overlap, inform one another, and support the same conclusion. The error arises when that relationship is assumed without examining the relevant evidence, legal provisions, moral principles, or consequences. Legal systems can prohibit conduct to prevent harm, protect rights, maintain public order, or implement collective decisions. The justification and effects of a particular prohibition must be assessed in context. Historical changes in law illustrate that legal classifications are not fixed across time. Conduct may be prohibited in one period and permitted in another, or treated differently by different jurisdictions. Such changes establish that legal status depends on the applicable legal framework; they do not independently settle the moral question. The same distinction applies to enforcement. Conduct may violate a legal requirement even if it is not detected or prosecuted. Conversely, an accusation or enforcement action does not, by itself, establish that the accused person committed the alleged violation. The correct method is to ask separate questions: What does the applicable law require? What evidence establishes the facts? Which moral or ethical standard is being applied? What consequences follow, for whom, and under what conditions? Which authority has jurisdiction to decide the question? Keeping these questions distinct prevents one classification from being mistaken for a complete answer. 4. The fallacy of opposition The fallacy of opposition, as defined in this document, occurs when a preferred position becomes the sole reference point for evaluation and any differing position is automatically classified as negative without independent examination. This is a descriptive label for a reasoning pattern, not a claim that every disagreement constitutes a formally recognized logical fallacy. The error converts a person's preference into a reference standard without establishing that the standard applies universally. Other positions are then evaluated by their relationship to that standard rather than by their content, evidence, purpose, or consequences. Several distinct logical relationships must be preserved. Difference is not contradiction. Two propositions may differ without one being the logical negation of the other. Contradiction is not the same as contrary opposition. Contradictory propositions cannot both be true in the same sense at the same time. Contrary propositions cannot both be true under the relevant conditions but may both be false. Contrast is not necessarily conflict. Two preferences may differ without interfering with each other. Conflict exists when their objectives, requirements, or effects are incompatible in the circumstances under consideration. Disagreement is not proof of error. Determining whether a position is factually incorrect requires examination of the relevant evidence and reasoning. Opposition is not proof of harm. A position that challenges an existing policy may identify a defect, propose an alternative, or introduce additional evidence. Whether it produces harm or benefit must be assessed independently. Not positive is not necessarily negative. If a position does not advance a particular objective, it does not follow that the position is harmful in every respect. These distinctions identify the underlying error: the automatic assignment of negative value to whatever differs from a preferred reference point. 5. The logical structure of the error The reasoning pattern can be expressed as a sequence of unsupported inferences: A person prefers a particular outcome. The preferred outcome is classified as good. A different outcome is classified as contrary to the preferred outcome. That difference is treated as opposition. The opposition is assigned a negative value. The negative classification is presented as an established property of the alternative itself. Each step requires independent justification. A preference does not establish universal goodness. A difference does not establish contradiction. A contradiction does not, by itself, establish which proposition is true. A legal classification does not settle every moral question. A negative evaluation under one criterion does not establish a negative evaluation under every criterion. Group agreement does not, by itself, establish universal validity. The principal errors that may be involved include: Category confusion: using a conclusion from one conceptual category as though it answered a question in another. False equivalence: treating materially different concepts as interchangeable. False dichotomy: presenting two alternatives as exhaustive when additional possibilities exist. Unsupported generalization: extending a conclusion beyond the evidence. Projection of evaluative judgment: attributing an observer's assessment to the subject as though it were an independently established property. These errors can occur together, but they are not identical. Accurate analysis requires identifying the actual inference being made rather than applying one label indiscriminately. 6. Minority judgment, public opinion, and political authority A minority judgment is a conclusion held by a group smaller than the relevant population. Its numerical status does not establish whether it is correct or incorrect. The same principle applies to majority judgments. The number of people holding a position and the evidential or moral justification for that position are separate questions. Political institutions nevertheless must make decisions through established procedures. Depending on the jurisdiction and subject, these procedures may include elections, legislative votes, judicial review, administrative decisions, constitutional requirements, and protections for individual rights. A decision made through a valid procedure may have legal effect without establishing that every affected person agrees with it or that every aspect of the decision is beyond criticism. Four distinctions are essential: Numerical support is not the same as factual accuracy. Legal authority is not the same as universal agreement. Public opinion is not necessarily uniform. Criticism of an institution is not automatically opposition to the entire political system. The error arises when a selected group's judgment is treated as a complete account of public opinion and every position outside that judgment is classified as invalid, harmful, or hostile without separate examination. 7. Governance without adequate experience or evidence Governance requires decisions about conditions experienced by individuals, communities, institutions, and industries. A policy may appear beneficial from the perspective of its designers while producing different consequences for the people subject to it. Direct experience can reveal practical constraints, unintended consequences, and differences between a policy's intended operation and its actual effects. Personal experience alone, however, does not establish the full effects of a policy. Reliable governance also requires relevant data, technical expertise, consultation, legal analysis, and evaluation of competing evidence. The structural failure occurs when decision-makers substitute assumptions for evidence or treat their own perspective as sufficient to represent everyone affected. Potential consequences include: Policies designed around conditions that do not exist in the affected community. Costs transferred to people who were not adequately considered during development. Benefits overstated because indirect effects or alternative outcomes were excluded. Implementation problems persisting because criticism is dismissed as opposition. Policies continuing after evidence undermines their original assumptions. The appropriate response is to establish procedures through which relevant experience, evidence, and competing perspectives inform decisions and through which outcomes can be evaluated and corrected. 8. Public opinion, framing, and selective information Public opinion can be influenced by how information is presented, which facts receive attention, how alternatives are described, and how frequently claims are repeated. These mechanisms do not establish that all public communication is manipulative or that observed public agreement is necessarily manufactured. They establish that expressed opinion must be interpreted in light of how information was collected and presented. A reasoning failure occurs when a preferred interpretation is presented as the only legitimate position, alternatives are characterized negatively without examination, and the resulting public response is then used as proof that the original interpretation was correct. This creates circular justification: the position is treated as correct because the public appears to support it, while the apparent support is interpreted through a presentation that already favors that position. A sound assessment distinguishes underlying evidence from its presentation. It examines question wording, the range of alternatives offered, the representativeness of the people consulted, data reliability, and the possibility that respondents understand the issue differently. Public opinion is evidence of what people express or believe under particular conditions. It is not, by itself, proof that a factual claim is true, a moral judgment is universally valid, or a policy produces its intended effects. 9. Freedom of belief and political disagreement Article 18 of the Universal Declaration of Human Rights recognizes freedom of thought, conscience, and religion, including the freedom to change religion or belief. Article 19 recognizes freedom of opinion and expression, including the freedom to hold opinions without interference. These are internationally recognized human-rights principles. Their precise legal implementation and enforceability depend on applicable treaties, domestic law, and the relevant institutional framework. A distinction must be maintained between holding a belief and acting on that belief. Freedom of belief does not automatically exempt every action motivated by a belief from otherwise applicable law. Restrictions on conduct, expression, or the manifestation of belief must be assessed under the relevant legal framework and human-rights standards. The reasoning error occurs when a belief is classified as unacceptable solely because it differs from an approved political position, or when disagreement is treated as sufficient evidence of illegality or harm. Political disagreement alone does not establish a legal violation. A person's belief, by itself, does not establish the legality or illegality of conduct associated with it. A political system that treats agreement as the condition for recognizing the legitimacy of a person's basic rights confuses political conformity with human dignity and legal protection. 10. Consequences of collapsing these distinctions When legal status, moral judgment, outcome, preference, and opposition are treated as interchangeable, identifiable failures may follow. Legal classification replaces substantive examination. Moral judgment becomes dependent exclusively on authority. Personal preference becomes a purported universal standard. Difference becomes hostility. Minority judgment becomes a substitute for public judgment. Public response becomes circular evidence. Governance becomes detached from consequences. Rights become improperly conditioned on agreement. These are possible structural consequences, not inevitable outcomes of every law, disagreement, political decision, or majority judgment. Establishing that a particular failure has occurred requires evidence of the relevant conduct, decision-making process, or consequences. 11. A consistent method of evaluation A consistent evaluation requires: Defining the claim. Identifying the applicable standard. Establishing the relevant facts. Separating evidence from inference. Considering reasonable alternatives. Assessing consequences independently. Distinguishing individual judgment from collective authority. Distinguishing disagreement from a violation. Revising conclusions when evidence changes. This method does not require every position to be treated as equally accurate, equally justified, or equally beneficial. It requires that differences in accuracy, justification, legality, and consequences be established through appropriate reasoning rather than inferred solely from a position's relationship to another. 12. Conclusion of Part I Wrong, illegal, bad, not good, universal, wanted, positive, negative, and opposed describe different concepts and relationships. Their meanings may overlap in particular circumstances, but they cannot be treated as universally interchangeable. Legal status does not independently settle every moral question. Moral judgment does not automatically establish legal status. An undesirable outcome under one criterion does not necessarily establish universal harm. The absence of a positive assessment does not necessarily establish a negative one. A difference of opinion does not establish contradiction, hostility, or wrongdoing. The fallacy of opposition arises when a preferred position becomes the reference point for all evaluation and every departure from that position is assigned a negative value without independent examination. In public policy, these distinctions permit disagreement without presuming hostility, criticism without presuming illegality, and legal authority without presuming universal moral agreement. A conclusion is justified by the evidence, applicable standards, and reasoning that support it, not merely by its classification, its acceptance by a group, or its opposition to a preferred view. PART II — FIVEO1 DEPARTMENT 69: PROPOSED LEGISLATIVE AND PROCUREMENT INITIATIVE 13. Title, purpose, and institutional status Proposed title: Fiveo1 Department 69 — Pharmaceutical API Exportation and Regional Supply-Chain Development Initiative Date: October 14, 2026 Proponent: Evan Winter, Fiveo1 Mailing address: P.O. Box 312786, Avalon, California 90704 This proposal seeks to develop a commercially viable, legally compliant supply channel for selected off-patent active pharmaceutical ingredients (APIs) manufactured by qualified suppliers in Mexico, Brazil, Argentina, Colombia, and Guatemala. The intended public-policy objectives are: Diversification of pharmaceutical input supply. Competitive sourcing from qualified manufacturers. Greater visibility into supplier origin, quality, and lot traceability. Reduction of avoidable supply-chain concentration where commercially and technically feasible. Transparent procurement pricing. Compliance with applicable U.S. import, drug-quality, controlled-substance, procurement, and biological-product requirements. Development of verifiable supplier and logistics relationships across the Americas. Institutional clarification: “Department 69” is a Fiveo1 project designation in this document. It is not represented as an existing California state department, a federal department, an established government contracting office, or an enacted legislative program. California Assembly District 69 is an actual legislative district. The district designation does not itself create a pharmaceutical procurement authority, appropriated funding, a government contract, or authority to bind a public agency. This document is a proposal for discussion and commercial development. Any legislative measure must be prepared and introduced through the appropriate legislative process. Any government supply arrangement must be awarded through the applicable procurement process and executed by an authorized contracting officer. 14. Parties and intended contracting structure Proposed supplier Fiveo1 P.O. Box 312786 Avalon, California 90704 Santa Catalina Island, California Proposed representative: Evan Winter Proposed buyer The specific United States government department, agency, subagency, or other authorized purchaser must be identified before execution. The buyer's legal name, contracting office, solicitation or contract number, authorized contracting officer, funding source, delivery destination, and applicable procurement clauses must be inserted into the final instrument. Proposed scope The supplier would seek to source, arrange importation of, and deliver selected APIs in accordance with an approved product schedule and the applicable contract. Fiveo1's status as a proposed supplier does not establish that it has been qualified, awarded a contract, authorized to import controlled substances, or approved to distribute any particular API. Before entering a transaction, the parties must establish whether Fiveo1 will act as the manufacturer, importer of record, distributor, broker, or procurement intermediary. Each role has different legal, regulatory, insurance, customs, and operational requirements. 15. Proposed procurement model The program would use a documented supplier-qualification process rather than relying solely on country of origin or a manufacturer's advertised product portfolio. Each proposed source must be assessed for: Legal identity and ownership. Manufacturing site and actual production capability. API-specific manufacturing authorization and regulatory status. FDA establishment registration and drug-listing requirements, as applicable. Current good manufacturing practice (CGMP) compliance. Applicable import restrictions, alerts, sanctions, and export controls. Product-specific specifications and pharmacopeial compliance. Lot-level certificate of analysis and traceability. Validated transportation, storage, and temperature requirements. Available production capacity, minimum order quantities, and lead times. Commercial quotations and payment terms. Insurance, recall procedures, quality agreements, and liability allocation. Country-level pharmaceutical capability is not proof that a named manufacturer currently produces a particular API at commercial scale. Every supplier-product-country combination must be verified separately. PART III — REGIONAL API PRODUCTION AND SOURCE-COUNTRY ASSESSMENT 16. Regional manufacturing background The Americas contain pharmaceutical formulation, chemical synthesis, biotechnology, and biological-product manufacturing capabilities. Those capabilities vary substantially by country, company, product, and manufacturing site. The presence of a finished-drug manufacturer does not establish domestic production of its APIs. A company may manufacture tablets, capsules, injectables, or biological medicines using imported active ingredients. The proposed sourcing countries are Mexico, Brazil, Argentina, Colombia, and Guatemala. They are candidate sourcing jurisdictions, not a blanket certification that all listed APIs are manufactured in those countries. 16.1 Mexico Mexico has a pharmaceutical manufacturing industry that includes finished dosage forms and certain API production. Candidate suppliers must be verified against the precise ingredient, manufacturing site, current production status, and applicable export permissions. The draft identifies Centrient Pharmaceuticals and Neolpharma/NeolSym as potential reference points for antibiotic and other API manufacturing. Their inclusion in a research list is not confirmation that every attributed ingredient is currently manufactured at a Mexican site or available for export to the United States. The following claims require product-level documentation before being used as sourcing commitments: Amoxicillin and ampicillin production. Cephalexin monohydrate, gentamicin sulfate, and lincomycin hydrochloride production. Methylphenidate hydrochloride, phenytoin, sodium phenytoin, diazepam, clonazepam, bromazepam, bezafibrate, nicardipine, and folic acid production. The stated number of API types and plants attributed to a named manufacturer. 16.2 Brazil Brazil has a substantial pharmaceutical sector, including chemical and biological manufacturing. Nortec Química and Fiocruz are identified as potential research targets for the proposed sourcing program. The draft identifies benznidazole, benzodiazepines, bupivacaine, prilocaine, esketamine, ibuprofen, dexamethasone, paclitaxel, fluorouracil, etoposide, simvastatin, prednisone, omeprazole, and insulin glargine-related production as areas for further verification. The precise claims about current manufacturing location, commercial scale, export availability, and the establishment of a first regional insulin glargine API plant must be supported by current primary-source documentation before being treated as established facts. The statement that Brazil imports approximately 90% of the APIs used by its pharmaceutical industry should not be treated as verified without a defined year, denominator, methodology, and authoritative source. 16.3 Argentina Argentina has pharmaceutical and biotechnology manufacturing capabilities. The draft identifies Triquim S.A. and Argentine biotechnology producers as potential sources or research targets. The proposed sourcing investigation includes remifentanil, benfotiamine, bosentan, imiquimod, meglumine antimoniate, rituximab, bevacizumab, interferon, erythropoietin, and growth hormone. Each ingredient requires separate verification of the current manufacturer, production site, approved product status, export permissions, and availability in the requested form and quality grade. Claims concerning the first Latin American biosimilar monoclonal antibodies and the commercial status of particular biotechnology products require dated, product-specific evidence before publication as definitive statements. 16.4 Colombia Colombia is included as a candidate sourcing jurisdiction. A company or facility must be identified for each ingredient proposed to be sourced there. The draft identifies PROQUIMES S.A. as a potential research target. No ingredient should be assigned to Colombia in a binding purchase schedule without verifying that the named facility actually manufactures that ingredient and is authorized to export it. 16.5 Guatemala Guatemala is included as a candidate regional sourcing and distribution jurisdiction. The draft identifies Luminova Pharma as a research target for generic pharmaceutical manufacturing. Manufacturing finished generic medicines does not establish that the company produces the underlying APIs. Each proposed API must be verified by product, facility, regulatory status, and available documentation. 16.6 Source-country determination The source country in the final schedule must refer to the actual API manufacturing site, not merely the seller's headquarters, distributor address, port of shipment, or country where the final product is repackaged. No supplier should be described as a confirmed source until the following have been obtained and reviewed: Legal manufacturer name and manufacturing address. Product-specific technical specification. Current production and export confirmation. Applicable regulatory registration or authorization. Quality documentation. Written price and capacity quotation. Verification that the proposed import pathway is lawful. PART IV — PROPOSED PRODUCT SCHEDULE 17. Scope of the candidate API schedule The following is a preliminary list of 38 candidate ingredients across eight categories. The list is a sourcing-development schedule, not a representation that all ingredients are currently available from the countries listed. The proposed source-country assignments remain subject to supplier verification. Category Candidate APIs Proposed source jurisdictions Antibiotics Amoxicillin; Ampicillin; Cephalexin monohydrate; Gentamicin sulfate; Lincomycin hydrochloride; Chloramphenicol Mexico; other countries only after verification Antiparasitic Benznidazole; Meglumine antimoniate Brazil; Argentina, subject to verification Central nervous system Methylphenidate hydrochloride; Phenytoin; Sodium phenytoin; Diazepam; Clonazepam; Bromazepam Mexico; Brazil, subject to verification Anesthetics and analgesics Bupivacaine; Prilocaine; Esketamine; Remifentanil; Ibuprofen Brazil; Argentina, subject to verification Cardiovascular Nicardipine; Bezafibrate; Simvastatin; Bosentan Mexico; Brazil; Argentina, subject to verification Oncology and steroids Paclitaxel; Fluorouracil; Etoposide; Dexamethasone; Prednisone Brazil; Mexico, subject to verification Other small molecules Omeprazole; Folic acid; Benfotiamine; Imiquimod Mexico; Brazil; Argentina, subject to verification Biologics and biotechnology-derived products Rituximab; Bevacizumab; Interferon; Erythropoietin; Growth hormone; Insulin glargine Argentina; Brazil, subject to product-specific verification Schedule count: 38 candidate ingredients. Important classification note: Rituximab, bevacizumab, interferons, erythropoietin, growth hormone, and insulin glargine are not interchangeable with conventional small-molecule APIs. Their regulatory status, manufacturing processes, quality controls, handling, and applicable product-approval requirements differ. The final contract must distinguish conventional chemical APIs from biotechnology-derived active substances and biological products. The term “off-patent” must also be verified at the relevant level. Patent status may vary by jurisdiction, formulation, process, indication, and specific product. Off-patent status does not remove regulatory, quality, import, or procurement requirements. 17.1 Controlled-substance review The initial draft marks diazepam, clonazepam, bromazepam, methylphenidate, remifentanil, and esketamine as controlled substances. This designation must not be treated as a final legal classification for every ingredient, formulation, salt, jurisdiction, or transaction. The final schedule must identify the applicable U.S. Controlled Substances Act schedule, relevant DEA registration category, import authorization, quota requirements where applicable, and any additional restrictions. No controlled-substance transaction may proceed until the parties have confirmed the applicable requirements with the Drug Enforcement Administration and other relevant authorities. PART V — PRICING METHODOLOGY AND MINIMUM MARGIN 18. Pricing formula The initial commercial model uses the following proposed pricing formula: Landed cost = documented supplier cost × 1.12 Contract floor = landed cost × 1.15 Equivalently: Contract floor = documented supplier cost × 1.12 × 1.15 The resulting contract floor is 1.288 times the supplier cost, representing a 28.8% markup on that cost. This is not the same as a 15% gross margin on the final selling price. A 15% markup on landed cost produces a gross margin of approximately 13.04% of the contract selling price when landed cost is the only cost of sales. If the intended requirement is a true minimum gross margin of 15% on the selling price, the formula must instead be: Contract floor = landed cost ÷ 0.85 The final agreement must specify which measure applies. The following schedule preserves the original requested formula as a 15% markup on landed cost, not a 15% gross margin. 19. Indicative low-end price schedule All figures below are preliminary estimates supplied for commercial planning. They are not verified current supplier quotations and must not be represented as established market prices or binding offers. API Indicative supplier cost/kg Landed cost/kg (× 1.12) Contract floor/kg (× 1.15) Ibuprofen $5.00 $5.60 $6.44 Folic acid $15.00 $16.80 $19.32 Amoxicillin $25.00 $28.00 $32.20 Ampicillin $30.00 $33.60 $38.64 Cephalexin $30.00 $33.60 $38.64 Chloramphenicol $40.00 $44.80 $51.52 Phenytoin $40.00 $44.80 $51.52 Gentamicin sulfate $100.00 $112.00 $128.80 Simvastatin $100.00 $112.00 $128.80 Lincomycin hydrochloride $150.00 $168.00 $193.20 Omeprazole $150.00 $168.00 $193.20 Prednisone $300.00 $336.00 $386.40 Fluorouracil $300.00 $336.00 $386.40 Diazepam* $300.00 $336.00 $386.40 Clonazepam* $800.00 $896.00 $1,030.40 Bupivacaine $800.00 $896.00 $1,030.40 Dexamethasone $1,000.00 $1,120.00 $1,288.00 Methylphenidate hydrochloride* $2,000.00 $2,240.00 $2,576.00 Etoposide $3,000.00 $3,360.00 $3,864.00 Paclitaxel $10,000.00 $11,200.00 $12,880.00 * Preliminary controlled-substance flag; final classification and authorization must be verified. The calculations above are arithmetically consistent with the stated formula. The underlying supplier-cost estimates have not been independently established as current, commercially available prices. 20. Pricing for remaining candidate APIs For benznidazole, bromazepam, prilocaine, esketamine, remifentanil, bezafibrate, nicardipine, bosentan, imiquimod, benfotiamine, meglumine antimoniate, and all biotechnology-derived ingredients, the proposed price is to be calculated from a current written supplier quotation. Each purchase order must attach: The supplier's dated quotation. The quoted product grade and specification. The manufacturing-site address. The currency, quantity, minimum order, and validity period. Freight and insurance assumptions. Customs, testing, handling, and storage charges. Applicable import authorization and permit costs. The agreed margin or markup calculation. No ingredient may be priced from an unverified estimate where a current quotation is required. 21. Landed-cost exclusions and commercial controls The initial 12% allowance is a proposed commercial assumption for freight, insurance, customs clearance, and lot testing. Actual costs may be higher or lower and must be documented. The allowance does not automatically include every cost associated with controlled-substance importation, customs brokerage, regulatory submissions, inspections, special handling, biological cold-chain logistics, product registration, or rejected shipments. The contract must specify whether these costs are included in the floor price or billed separately. No order should be accepted below the agreed minimum pricing threshold unless an authorized written amendment changes the pricing terms. PART VI — REGULATORY, QUALITY, AND PROCUREMENT COMPLIANCE 22. FDA requirements for imported APIs APIs imported or offered for import into the United States must comply with the applicable provisions of the Federal Food, Drug, and Cosmetic Act and relevant regulations in Title 21 of the Code of Federal Regulations. FDA's guidance on API imports identifies requirements that may include foreign-establishment registration, drug listing, labeling, and applicable CGMP compliance. The precise requirements depend on the ingredient, intended use, import pathway, and product circumstances. Official reference: https://www.fda.gov/drugs/human-drug-imports/importing-active-pharmaceutical-ingredients General human-drug import requirements: https://www.fda.gov/drugs/human-drug-imports/general-requirements-importing-human-drugs The final contract must not assume that registration alone authorizes every product for import or commercial distribution. Some products require an applicable approved drug application or another lawful pathway. The supplier and importer must establish the relevant requirements before shipment. 23. Quality assurance and lot acceptance Each applicable shipment must be accompanied by product-specific quality documentation, including: Manufacturer-issued certificate of analysis. Lot or batch identification. Identity, strength, purity, and relevant impurity results. Applicable USP, European Pharmacopoeia, or other contractually accepted specifications. Testing documentation from a qualified laboratory where required. Manufacturing and expiry or retest information, as applicable. Storage, transport, and handling instructions. Traceability records and deviation documentation. A certificate of analysis does not, by itself, establish full regulatory compliance. Testing methods, laboratory qualification, specifications, and acceptance criteria must be defined in the quality agreement. The contract must provide for quarantine, rejection, investigation, replacement, refund, recall cooperation, and allocation of costs for nonconforming lots. 24. Controlled substances and DEA requirements Before importing any ingredient that is a controlled substance under U.S. law, the responsible parties must establish the applicable registration, import-permit, quota, reporting, security, and recordkeeping requirements. The DEA's quota guidance describes requirements for specified controlled-substance activities, including import quotas in applicable circumstances. Official reference: https://www.deadiversion.usdoj.gov/quotas/quota-apps.html The final schedule must not presume that every ingredient marked with an asterisk is subject to the same quota or permit rules. The legal classification and requirements must be confirmed for each substance and transaction. All required approvals must be obtained before shipment. Permit and quota costs must be allocated explicitly in the contract. 25. Biological products and biotechnology-derived ingredients The biological-product portion of the schedule requires a separate regulatory assessment. A biological active substance is not automatically eligible for import or commercial distribution merely because a related product is marketed abroad or a patent has expired. Depending on the intended use and product, the relevant pathway may involve a biologics license application, another applicable approval, or a lawful investigational or other specific pathway. The FDA's general human-drug import guidance describes the role of applicable NDA, ANDA, IND, and BLA requirements. Official reference: https://www.fda.gov/drugs/human-drug-imports/general-requirements-importing-human-drugs The final contract must distinguish between an API-only transaction and the importation or distribution of a finished biological drug product. Product classification, authorization, cold-chain requirements, analytical comparability, sterility or contamination controls, and other quality obligations must be determined for the specific product. 26. U.S. government procurement No U.S. government agency is a party to this proposal until it has accepted a legally valid procurement instrument executed by an authorized contracting officer. The final agreement must identify the agency, solicitation or contract number, appropriation or funding authority, scope, quantity, delivery schedule, inspection requirements, payment terms, applicable procurement clauses, and dispute procedures. Where applicable, procurement must comply with the Federal Acquisition Regulation, agency-specific supplements, competition requirements, domestic-preference provisions, country-of-origin restrictions, sanctions, and other applicable rules. The parties must verify that the proposed sourcing countries, manufacturers, products, and intermediaries are eligible for the specific procurement. The presence of a proposed supplier in this document does not establish eligibility for a government award, a sole-source basis, a government endorsement, or an obligation to purchase. PART VII — PROPOSED SCIENTIFIC AND BIOLOGICAL INFRASTRUCTURE 27. California High Desert and Inland Empire site framework The initial proposal identifies the following locations in San Bernardino County, California, for preliminary consideration in scientific exploration, combination development, biological research support, and related infrastructure planning: Apple Valley. Victorville. Big Bear Lake. Silverwood Lake. Spring Valley Lake. Mojave Narrows Regional Park. Jess Ranch Fish Hatchery, Apple Valley. These are candidate geographic references, not confirmed or authorized project facilities. No property, park, lake, hatchery, laboratory, or other facility is designated as an approved Fiveo1 operating site merely by appearing in this document. Use of any location requires confirmation of ownership, operator permission, zoning, land-use restrictions, environmental requirements, permits, and any applicable research or animal-care approvals. 27.1 Scientific exploration and combination development Potential activities may include nonclinical research, analytical testing, formulation feasibility, materials characterization, biological process development, and evaluation of supporting infrastructure, subject to the applicable approvals and facilities. Any work involving human biological material, transplantation, animals, genetically modified organisms, pathogens, regulated biological agents, or clinical applications must undergo the relevant legal, ethical, biosafety, and institutional review before implementation. 27.2 Jess Ranch Fish Hatchery Jess Ranch Fish Hatchery is identified as a candidate research reference because of its association with aquaculture. The specific claims concerning on-site production, vaccination, species, current operations, and any suitability for the proposed work require confirmation from the operator and relevant authorities. An aquaculture facility is not automatically suitable or authorized for pharmaceutical manufacturing, transplantation research, clinical research, or other regulated biological activities. 27.3 Site approval requirements Before designating any site for an actual project, Fiveo1 must document: The owner and operator. The exact physical address and parcel. Written permission or lease. Applicable planning and environmental approvals. Permitted research and operational activities. Required laboratory, biosafety, and quality systems. Waste management and emergency procedures. Required insurance and professional oversight. Funding and responsible operating entity. No activity is authorized by this proposal alone. PART VIII — SOURCE-SIDE LOCATION AND DEVICE METADATA 28. Submitted metadata record The initial draft includes the following source-side metadata: IP address: 190.143.186.107. Reported network: Telecomunicaciones de Guatemala / Claro network. Device description: Mozilla/5.0 (Linux; Android 10; K) AppleWebKit/537.36 (KHTML…). Screen dimensions: Unknown. Reported coordinates: 14.738654, -91.158361. Reported location description: Calle 15 de Febrero, Guatemala. These values are retained as submitted metadata, not as independently verified facts. The IP-to-provider attribution requires confirmation through a current IP registration or network lookup. An IP address does not independently prove a person's identity or exact physical location. Coordinates may originate from a device, browser, mapping service, or manually entered record; their provenance must be documented. The coordinates are consistent with the general Panajachel/Lake Atitlán area of Guatemala, but the specific street-level description and exact placement require mapping verification. Device and location data should be retained only for a defined operational purpose, with appropriate access controls, accuracy labels, and privacy safeguards. The metadata does not establish a supplier's identity, a manufacturing site, a government relationship, or the origin of a pharmaceutical ingredient. PART IX — GOVERNMENT, LEGISLATIVE, REGULATORY, AND MUNICIPAL CONTACTS 29. California Assembly District 69 The official California State Assembly page identifies Josh Lowenthal as the Assembly Member for District 69 in the information retrieved for this document. Official legislator page: https://www.assembly.ca.gov/assemblymembers/69 Sacramento office California State Assembly P.O. Box 942849 Sacramento, CA 94249-0069 Capitol office 1021 O Street, Suite 8320 Sacramento, CA 95814 Telephone: (916) 319-2069 District office 3777 Long Beach Boulevard, Suite 260 Long Beach, CA 90807 Telephone: (562) 366-2769 Official source: California State Assembly, Assembly Member District 69. The district office is a relevant channel for submitting a proposal or requesting information about legislative procedures. Its inclusion does not mean the Assembly Member endorses this proposal or that the document has been introduced as a bill. 29.1 Legislative submission and identification The proponent may submit this document for review and request guidance on: Whether the proposal is appropriate for state legislation, federal legislation, or a commercial procurement process. Which committee or agency has jurisdiction. Whether a formal bill request or legislative counsel review is appropriate. Which procurement, pharmaceutical, public-health, or economic-development authorities should be consulted. A proposed legislative document should not be represented as an enacted bill or an official Assembly measure until it has been formally introduced and assigned the relevant bill number. 30. City of Avalon — City Hall and City Council The City of Avalon's official website identifies the following contact information. Physical address City Hall 410 Avalon Canyon Road Avalon, CA 90704 Mailing address P.O. Box 707 Avalon, CA 90704 Main telephone: (310) 510-0220 Website: https://www.cityofavalon.gov/ City Council: https://www.cityofavalon.gov/216/City-Council City Manager's Office: https://www.cityofavalon.gov/159/Administration-City-Managers-Office City Clerk: https://www.cityofavalon.gov/161/City-Clerk The City of Avalon is a municipal government contact, not the proposed buyer or regulator for the federal API procurement program. 30.1 Identified municipal contacts Ann Marshall — Mayor Officially listed telephone: (310) 339-2935. Officially listed email: amarshall@cityofavalon.gov. David Maistros — City Manager Main office: (310) 510-0220. Extension: 122. Official city contact page: https://www.cityofavalon.gov/159/Administration-City-Managers-Office. Gabrielle Morones — City Clerk Main office: (310) 510-0220. Extension: 119. Official city contact page: https://www.cityofavalon.gov/161/City-Clerk. Additional listed council contacts Lisa Lavelle — llavelle@cityofavalon.gov. Donna Lopez — dlopez@cityofavalon.gov. Michael Ponce, Mayor Pro Tem — mponce@cityofavalon.gov. Yesenia De La Rosa — ysdelarosa@cityofavalon.gov. Official directory: https://www.cityofavalon.gov/m/directory Contact information and officeholders should be rechecked on the official city website immediately before sending or executing a document. A public contact listing is not evidence of consent, sponsorship, or contract approval. 31. Federal pharmaceutical and procurement authorities The following are official starting points for regulatory verification and procurement procedures. 31.1 U.S. Food and Drug Administration Subject: API import compliance, establishment registration, drug listing, product approval, and quality requirements. API import guidance: https://www.fda.gov/drugs/human-drug-imports/importing-active-pharmaceutical-ingredients General human-drug import requirements: https://www.fda.gov/drugs/human-drug-imports/general-requirements-importing-human-drugs FDA import information: https://www.fda.gov/industry/importing-fda-regulated-products/importing-human-drugs These official pages are the primary starting points for determining which FDA requirements apply to a proposed ingredient and import pathway. 31.2 Drug Enforcement Administration Subject: Controlled-substance registration, import authorization, quota questions, and compliance. DEA Diversion Control Division: https://www.deadiversion.usdoj.gov/ Quota applications: https://www.deadiversion.usdoj.gov/quotas/quota-apps.html The relevant DEA office and requirements depend on the specific substance and proposed activity. The final contract must not substitute this general contact route for product-specific authorization. 31.3 U.S. government contracting Subject: Agency identification, procurement opportunities, solicitation requirements, and authorized contracting officers. SAM.gov: https://sam.gov/ Federal Acquisition Regulation: https://www.acquisition.gov/far The buyer and solicitation must be identified before a government contract can be completed. Fiveo1 should use the relevant agency's official procurement channels and verify the contracting officer's authority. 32. Fiveo1 supplier contact Fiveo1 P.O. Box 312786 Avalon, California 90704 Santa Catalina Island, California Proposed representative: Evan Winter No telephone number or email address for Fiveo1 is supplied in this proposal. None is invented here. Any public-facing contact details must be provided and verified by Fiveo1 before distribution. PART X — GENERAL COMMERCIAL TERMS 33. Minimum price and margin The preliminary pricing method applies the agreed supplier-cost and landed-cost assumptions to the applicable purchase order. No sale should proceed below the contract floor established in the executed agreement. The parties must distinguish markup on landed cost from gross margin on selling price. Any change to the pricing formula must be documented in writing. 34. Supplier quotations All final purchase orders must include current written quotations from the actual manufacturer or authorized supplier, including product identity, grade, specifications, quantity, price, lead time, shipping terms, and quotation validity. Indicative estimates in this document must be replaced by documented quotations before a binding transaction. 35. Source countries and traceability The proposed sourcing jurisdictions are Mexico, Brazil, Argentina, Colombia, and Guatemala. The actual manufacturing country and site must be identified for every lot. Country-of-origin declarations, export documents, shipping records, and manufacturing documentation must be consistent. No ingredient may be assigned to a country solely because a distributor or trading company is located there. 36. Quality Products must meet the applicable specifications agreed in the quality agreement and all relevant legal requirements. The parties must establish lot acceptance criteria, testing responsibilities, record retention, audit rights, change control, deviations, complaint handling, recall cooperation, and liability for defective or misrepresented materials. 37. Delivery and risk of loss Delivery terms, named destination, shipping method, insurance, customs responsibilities, inspection, and title and risk transfer must be stated in each purchase order. The initial proposal contemplates transfer of title and risk upon delivery to the designated U.S. government receiving facility. That provision must be reconciled with the final delivery term, applicable law, and the government's contract clauses. 38. Payment Payment terms must be established by the executed agreement or purchase order. No payment schedule, government funding commitment, or credit arrangement is created by this proposal. 39. Rejection, termination, and liability The final agreement should establish: Rejection of nonconforming or improperly documented goods. Replacement, refund, or other remedies. Responsibility for testing, detention, storage, and disposal. Product recall and adverse-event cooperation, as applicable. Indemnification and insurance. Termination for default, regulatory failure, or convenience where contractually permitted. Dispute resolution and applicable governing law. Records retention and audit rights. 40. Governing law The original proposal specifies California law and applicable federal procurement regulations. The final agreement must be reviewed to determine the appropriate governing-law clause, federal procurement terms, jurisdiction, and dispute procedures. A California-law clause cannot displace mandatory federal statutes, federal procurement requirements, or other applicable law. PART XI — EXECUTION CONDITIONS AND REPRESENTATIONS 41. Conditions precedent to a binding contract No binding API purchase or government supply obligation should arise until all applicable conditions have been satisfied, including: Identification of the buyer and authorized contracting officer. Confirmation of the supplier's legal identity and capacity. Product-by-product manufacturer and site verification. Written commercial quotations. Applicable FDA registration, listing, and product-pathway verification. Controlled-substance authorization where required. Biological-product pathway determination where applicable. Quality agreement and lot-acceptance criteria. Import, export, customs, and transportation arrangements. Funding, purchase order, and delivery authorization. Final review of applicable procurement clauses and governing law. 42. Representations and limitations This proposal is a statement of intended objectives and a preliminary commercial framework. It does not represent that: Fiveo1 has been awarded a U.S. government contract. Any government agency has accepted or endorsed the proposal. Every named company manufactures the attributed ingredients at a particular site. The preliminary supplier prices are current market quotations. The listed biological products are automatically eligible for import. All candidate APIs are legally unrestricted or available for export. The identified scientific sites have approved the proposed activities. The proposed program has received legislative approval, appropriations, or regulatory authorization. All such matters require documentary verification and, where applicable, formal approval. PART XII — SIGNATURE AND SUBMISSION 43. Proposed supplier signature Fiveo1 Represented by: Evan Winter Mailing address: P.O. Box 312786, Avalon, California 90704 Signature: ____________________________________ Date: _________________________________________ 44. Proposed government buyer signature United States Government Agency: ____________________________________ Agency and contracting office: ________________________________________ Authorized contracting officer: _______________________________________ Solicitation or contract number: ______________________________________ Signature: ____________________________________ Date: _________________________________________ The government buyer's signature section is for completion only if an authorized agency enters into a valid contract. It does not imply that a government agency is currently a party to this proposal. FINAL STATEMENT Fiveo1 proposes a framework for distinguishing factual claims, legal classifications, moral judgments, public opinion, political authority, and the evaluation of consequences while developing a verifiable pharmaceutical API sourcing and procurement initiative. The analytical framework requires that disagreement not be mistaken for proof of error, opposition not be mistaken for proof of harm, public support not be mistaken for proof of factual accuracy, and legal status not be mistaken for a complete moral assessment. The proposed pharmaceutical initiative applies the same principle operationally: country-level capability is not proof of product availability; an indicative price is not a verified quotation; an identified agency is not a contracting party; and a proposed activity is not an authorized activity. The program must proceed through evidence, supplier verification, applicable legal standards, quality controls, transparent pricing, and authorized procurement procedures. FIVEO1 Evan Winter P.O. Box 312786 Avalon, California 90704 Santa Catalina Island, California Document date: October 14, 2026